• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What We're Reading: House Passes CHIP Funding; Cancer Blood Test; Drug Policy Office Budget

Article

House passes spending bill that includes funding for the Children's Health Insurance Program for 6 years; researchers work on an experimental blood test that could detect 8 cancers; President Donald Trump plans to slash the budget of the Office of National Drug Control Policy by as much as 95%.

House Passes CHIP Funding as Part of Spending Bill

By a vote of 230 to 197, the House of Representatives passed a spending bill that would a government shutdown. According to The New York Times, the bill provides funding for the Children’s Health Insurance Program (CHIP) for 6 years. However, Senate Republicans are unlikely to sway enough Democratic votes. Democrats want more concessions as part of the spending bill, including a stronger government response to the opioid epidemic and protection for young immigrants brought to the country illegally when they were children.

Blood Test Could Detect 8 Cancers

A blood test in development might be able to detect 8 common cancers in the earliest stages, when those cancers are treatable. Researchers hope that the experimental test—which focuses on breast, colon, esophagus, liver, lung, ovarian, pancreas, and stomach cancers—will only cost $500, reported NPR. The researchers reported that, while the test was only successful 40% of the time in patients with stage 1 cancers, the finding still represents an important milestone in detecting cancers.

Trump Plans to Slash Drug Policy Office Budget

The budget of the Office of National Drug Control Policy could be cut by as much as 95%, according to plans from President Donald Trump. The office is responsible for coordinating the government’s response to the opioid crisis, according to Politico. The reduction in funding would mean moving the office’s 2 main grant programs to HHS and the Justice Department. The administration tried to eliminate those grant programs earlier, but received pushback from both parties.

Related Videos
Video 6 - "Closing Thoughts on the Current Ovarian Cancer Treatment Landscape"
Video 5 - "Harnessing Biomarkers & Molecular Profiling in Ovarian Cancer Treatment"
Video 7 - "Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients"
Video 6 - "Current Front-Line Targeted Treatments in Ph+ ALL"
Video 6 - "Community Partnership: Increasing Public Awareness of CVD"
Video 5 - "Peripheral Arterial Disease Awareness for Minority Populations"
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.